A Pathological Complete Response in Malignant Pleural Mesothelioma after Combination Chemotherapy with Carboplatin and Pemetrexed  by Kao, Steven Chuan-Hao et al.
CASE REPORT
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A 57-year-old nonsmoking male with previous asbestosexposure presented with a year history of right pleural
effusion and 2-month history of night sweats and increasing
chest pain. A mini thoracotomy, biopsy, and pleurodesis were
performed. Intraoperatively, 1 liter of viscous yellow fluid
was aspirated, and widespread dense infiltration of the pari-
etal pleura was noted.
The pleural biopsy confirmed malignant pleural me-
sothelioma (MPM) of epithelioid subtype (Figures 1A, B).
His disease was staged with a computed tomography scan,
which demonstrated disease in the right hemithorax only.
He underwent six cycles of chemotherapy consisting of
pemetrexed (500 mg/m2) and carboplatin (area under the
curve 5) every 3 weeks. Carboplatin was used due to preex-
isting hearing impairment. He tolerated it well with grade II
anemia and grade I fatigue and nausea. A restaging computed
tomography scan demonstrated a reduction of pleural thick-
ness indicative of a radiologic partial response.
Given the good response to chemotherapy with no
extrathoracic disease, an extrapleural pneumonectomy (EPP)
was performed 4 weeks postchemotherapy. He had no sig-
nificant postoperative complications.
A thorough examination of the pathologic specimens
consisting of the right lung, pleura, hilar and mediastinal
nodes, and port site demonstrated no residual malignancy.
No adjuvant radiotherapy was given. He remains well
without any evidence of recurrence 1 year postsurgery.
DISCUSSION
Treatment with cisplatin/pemetrexed in MPM has re-
sulted in a 3-month survival benefit and improvement in
quality of life.1 Although the objective radiologic response
rate is about 40%, the majority of responses are partial rather
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FIGURE 1. A, Malignant mesothelioma infiltrating the
pleura and subpleural adipose tissue (at 40). B, Mesothelial
cells positive for calretinin stain (at 200).
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than complete. A search in the literature yielded no radiologic
complete response (CR) in the cisplatin/pemetrexed combi-
nation1 but up to 4% achieving radiologic CR with carbopla-
tin/pemetrexed in a phase II trial.2 Nevertheless, the CRs
were not confirmed pathologically.
The treatment protocol of induction chemotherapy fol-
lowed by EPP allows us to examine the pathologic response
after chemotherapy. None of the studies confirmed a patho-
logic CR after three to four cycles of chemotherapy with cispla-
tin/gemcitabine3 or carboplatin/gemcitabine.4 Krug et al.5 re-
cently reported their phase II trial using cisplatin/pemetrexed
followed by EEP and radiotherapy. Three pathologic CRs were
reported, which represented 5% of patients undergoing EPP.
Despite the often difficult pathologic diagnosis of me-
sothelioma, we believe that our patient had MPM, given the
two independent pathologic reviews of the initial biopsy
confirming the invasive nature of the tumor and immunohis-
tochemical evidence of mesothelial origin, as well as the
supportive clinical picture of increasing pulmonary symp-
toms, and the typical radiologic changes. Furthermore, the
radiologic response seen after chemotherapy lends further
support to a malignant process rather than a benign one.
Therefore, we believe that this is the first reported case
of a pathologic CR in a patient with MPM after carboplatin/
pemetrexed. In patients whom cisplatin is contraindicated,
carboplatin seems to be a reasonable alternative in combina-
tion with pemetrexed.
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